🏛️ Verified NIH Record • Updated 2026-04-15
Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease (NCT06046248)
Phase II Trial of Belumosudil and Rituximab for the Primary Treatment of Extensive Chronic Graft-versus-host Disease
🟢 Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Northside Hospital, Inc.
🩺 Plain-English Summary (8th-Grade Level)
This is an open-label, Phase 2 study designed to evaluate the safety and efficacy of belumosudil and rituximab as primary treatment of cGVHD.
Who can join: Review the eligibility criteria below.
Location: Northside Hospital — Atlanta, Georgia
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Northside Hospital — Atlanta, Georgia
📞 Contact the Study Coordinator
Phone: (404) 255-1930
Email: ssolomon@bmtga.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Chronic Graft Versus Host Disease
- Predicting the Quality of Response to Specific Treatments in Patients With cGVHD, PQRST Study — Gainesville, Florida
- Leflunomide in Treating Patients With Steroid Dependent Chronic Graft Versus Host Disease — Duarte, California
- Trial of Regulatory T-cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease — Boston, Massachusetts
- Improving Outcomes Assessment in Chronic GVHD — Stanford, California
- A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease. — Little Rock, Arkansas
- Mindfulness Intervention to Reduce Patient Reported Symptoms in Patients With Chronic Graft-Versus-Host Disease — Duarte, California
Explore by condition: All Chronic Graft Versus Host Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.